Has Cheryl Burgess, MD received payments from drug or device companies?

Yes. Drug and device makers reported $445,341 in general payments to Cheryl Burgess, MD across 406 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Cheryl Burgess, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Cheryl Burgess, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Cheryl Burgess, MD

Procedural Dermatology · Washington, DCNPI 1881756872

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $335,330 of the $445,341 with a category attached, or 75.3%. 19 manufacturers reported payments, led by AbbVie at 51.1% of the total. Reporting peaked in 2024 at $130,967 and has fallen 78.2% since, to $28,509 in 2025.

$445,341in general payments, 2019–2025

Across 406 payments — averaging $1096.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$228K
Merz North America, Inc.$162K
Incyte Corporation$35K
UCB, Inc.$12K
Strata Skin Sciences, Inc.$2K
Janssen Scientific Affairs, LLC$2K
plus $4K from 13 others

$1,909,759in research payments, 2019–2025

Across 156 payments — averaging $12,242 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

AbbVie$1.3M
Merz North America, Inc.$405K
Janssen Research & Development, LLC$74K
Aclaris Therapeutics, Inc.$68K
Journey Medical Corporation$64K
Pfizer$14K

What the payments were for

Consulting fees$335,33075%
Speaking & faculty fees$48,20511%
Travel & lodging$35,0438%
Food & beverage$13,1223%
Education$640%
Gifts$13,5773%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie(2 entities)	165	$227,768
Merz North America, Inc.	120	$162,258
Incyte Corporation	44	$35,128
UCB, Inc.	2	$12,280
Strata Skin Sciences, Inc.	6	$2,178
Janssen Scientific Affairs, LLC	1	$2,013
Medimetriks Pharmaceuticals, Inc.	38	$1,047
Endo Pharmaceuticals Inc.	2	$826
Aclaris Therapeutics, Inc.	2	$520
Regeneron Healthcare Solutions, Inc.	5	$403
Sanofi	2	$401
Galderma Laboratories, L.p.	7	$134
Solta Medical, A Division Of Bausch Health US, LLC	1	$109
Almirall LLC	2	$73
Revance Therapeutics, Inc.	3	$65
E.r. Squibb & Sons, L.L.C.	2	$47
Journey Medical Corporation	1	$41
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	2	$34
Sun Pharmaceutical Industries Inc.	1	$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

XEOMIN$47,828
OPZELURA$31,097
BOTOX$21,864
NATRELLE SALINE-FILLED BREAST IMPLANTS$15,819
BOTOX COSMETIC$5,916
Skyrizi$5,430
Rinvoq$2,715
Tremfya$2,013
XTRAC$1,966
ESKATA$500
Neo-Synalar$377
DUPIXENT$292
ASCLERA$250
Clindacin ETZ$153

How this compares

Too few procedural dermatology providers in District of Columbiato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024

$38,729

Medicare patients

117

Services billed

305

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Clobetasol Propionate	20	$1,200
Minoxidil	36	$520
MethotrexateMethotrexate Sodium	13	$111

Paid to pharmacies, not to this prescriber.

Other procedural dermatology in Washington

Sara HoganWashington$32K
Nina HartmanWashington$10K

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →